183 related articles for article (PubMed ID: 10376978)
1. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin.
Kovacs MS; Hocking DJ; Evans JW; Siim BG; Wouters BG; Brown JM
Br J Cancer; 1999 Jun; 80(8):1245-51. PubMed ID: 10376978
[TBL] [Abstract][Full Text] [Related]
2. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
3. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
4. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
5. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
Siim BG; Menke DR; Dorie MJ; Brown JM
Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
Papadopoulou MV; Ji X; Bloomer WD
J Exp Ther Oncol; 2006; 5(4):261-72. PubMed ID: 17024967
[TBL] [Abstract][Full Text] [Related]
7. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
8. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
[TBL] [Abstract][Full Text] [Related]
9. Tirapazamine: laboratory data relevant to clinical activity.
Brown JM; Wang LH
Anticancer Drug Des; 1998 Sep; 13(6):529-39. PubMed ID: 9755717
[TBL] [Abstract][Full Text] [Related]
10. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
11. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine.
Dorie MJ; Brown JM
Cancer Chemother Pharmacol; 1997; 39(4):361-6. PubMed ID: 9025778
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA replication by tirapazamine.
Peters KB; Wang H; Brown JM; Iliakis G
Cancer Res; 2001 Jul; 61(14):5425-31. PubMed ID: 11454687
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo.
Masunaga S; Tano K; Watanabe M; Kashino G; Suzuki M; Kinashi Y; Ono K; Nakamura J
Br J Radiol; 2009 May; 82(977):392-400. PubMed ID: 19153181
[TBL] [Abstract][Full Text] [Related]
15. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
[TBL] [Abstract][Full Text] [Related]
16. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
Evans JW; Yudoh K; Delahoussaye YM; Brown JM
Cancer Res; 1998 May; 58(10):2098-101. PubMed ID: 9605751
[TBL] [Abstract][Full Text] [Related]
17. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
18. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic Therapy with Liposomal Zinc Phthalocyanine and Tirapazamine Increases Tumor Cell Death via DNA Damage.
Broekgaarden M; Weijer R; van Wijk AC; Cox RC; Egmond MR; Hoebe R; van Gulik TM; Heger M
J Biomed Nanotechnol; 2017 Feb; 13(2):204-20. PubMed ID: 29377650
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of bioreductive drug tirapazamine is increased by application of electric pulses in SA-1 tumours in mice.
Cemazar M; Parkins CS; Holder AL; Kranjc S; Chaplin DJ; Sersa G
Anticancer Res; 2001; 21(2A):1151-6. PubMed ID: 11396155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
